The current work found that the downstream targets of HIF-1α activity, metabolic markers Ang2, GLUT1, LDHA, and PDK1, which equip the tumor for survival and growth under hypoxic conditions (43, 44), were also downregulated by anlotinib plus bevacizumab. The gene discussed is SLC2A1; the disease is neoplasm.